The Pharma Data

OCTOBER 14, 2020

15, 2020 (GLOBE NEWSWIRE) — Eloxx Pharmaceuticals, Inc. Conference Call Information : Date : Thursday, November 5, 2020. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases.

Pharmaceuticals 52

Pharmaceuticals RNA Small Molecule Protein Production 52

The Pharma Data

NOVEMBER 30, 2020

Biohaven acquires exclusive global rights to a portfolio of novel, small-molecule CGRP antagonists. We are now committed to pursuing other CGRP-mediated diseases through advancing novel investigational agents such as HTL0022562 into human studies.” TOKYO and CAMBRIDGE, England , Dec. Vlad Coric , M.D.,

Small Molecule 40

Small Molecule Licensing Licensing Treatment 40

The Pharma Data

NOVEMBER 19, 2020

20, 2020 /PRNewswire/ — Sosei Group Corporation (“the Company”) (TSE: 4565) announces a progress update for its R&D program focused on the design and development of novel drugs targeting the SARS-CoV-2 coronavirus and to treat COVID-19. The program was initiated in April 2020. References. Hilgenfeld, Febs J.

Small Molecule 40

Small Molecule Structure Based Drug Design (SBDD) Molecular Biology International 40

New Drug Approvals

SEPTEMBER 23, 2024

Target: DNA/RNA Synthesis Pathway: Cell Cycle/DNA Damage Huntington’s disease (HD) is a progressive, autosomal dominant neurodegenerative disorder of the brain, having symptoms characterized by involuntary movements, cognitive impairment, and mental deterioration. 2020-01-02. SCHEME PATENT PTC Therapeutics Inc., Audiol Res. J Pers Med.

Small Molecule 57

Small Molecule RNA DNA Disease 57

Drug Target Review

SEPTEMBER 25, 2024

Applying our technology has enabled us to develop a new small molecule, TT125-802, and to assign a new role to the epigenetic regulator CBP/p300 as a novel master regulator of non-oncogene resistance. This orally available small molecule binds to the bromodomain of CBP/p300 in a highly specific manner.

Small Molecule 105

Small Molecule Therapies Regulations Treatment 105

Drug Target Review

OCTOBER 4, 2023

Antibody-drug conjugates (ADCs) have been a groundbreaking approach to cancer treatment with their ability to deliver cytotoxic drugs directly to diseased cells while sparing healthy tissues. Groundbreaking strategies like proteolysis-targeting chimeric molecules (PROTACs) are also being explored. 52 , 79–91 (2020).

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

The Pharma Data

OCTOBER 27, 2021

Small molecule candidate Anle138b targets disease modification for multiple system atrophy and other neurological disorders. Anle138b targets pathological alpha-synuclein oligomers and is being evaluated in patients with neurodegenerative diseases for potential disease modification. Multiple System Atrophy.

Licensing 52

Licensing Licensing Disease Small Molecule 52

The Pharma Data

MAY 31, 2022

BIIB122 is an inhibitor of LRRK2, a potential novel target intended to impact the underlying biology and slow the progression of Parkinson’s disease Phase 2b LUMA to enroll approximately 640 participants with early-stage Parkinson’s disease; most advanced clinical study of a LRRK2 inhibitor. Denali Therapeutics Inc.

Disease 52

Disease Small Molecule Engineering Biosimilars 52

New Drug Approvals

SEPTEMBER 29, 2024

link] 01 Aug 2022 Cortexyme is now called Quince Therapeutics You need to be a logged in or subscribed to view this content This small molecule is an orally available protease inhibitor targeting the lysine proteases of the periodontal pathogen Porphyromonas gingivalis. gingivalis is associated with cardiovascular disease.

Small Molecule 62

Small Molecule DNA Disease Trials 62

The Pharma Data

JANUARY 5, 2021

Durham, North Carolina-based Ribometrix announced a strategic collaboration deal with Genentech , a Roche company, to identify and advance novel RNA-targeted small molecule therapeutics. This is because many proteins do not have small-molecule binding sites. This is not the first deal for RNA therapeutics for Genentech.

RNA 52

RNA Small Molecule DNA Licensing 52

Drug Target Review

DECEMBER 21, 2023

All of these are novel targets to be explored in small molecule drug discovery as well as for improving the efficacy of mRNA vaccines. And really, this comes to the biggest question of all: what is the underlying mechanism of a given disease? And this is exactly where AI can provide us with an extremely powerful new strategy.

Disease 105

Disease Small Molecule Vaccine Drugs 105

The Pharma Data

DECEMBER 15, 2020

A healthy immune system defends the body against disease and other conditions. Autoimmune disease impacts different parts of the body, weakening functionality. Researchers are aware of more than 80 diseases that occur when the immune system attacks the body’s own organs, tissues and cells. It may be life-threatening.

Disease 52

Disease Clinical Trials Small Molecule Trials 52

The Pharma Data

NOVEMBER 18, 2020

Presentations to highlight the OBI-833 Phase 1 clinical study results in non-small cell lung cancer (NSCLC) and the dose escalation cohort. 19, 2020 /PRNewswire/ — OBI Pharma, Inc. Session Date and Time: Friday, November 20, 2020. Session Date and Time: Friday, November 20, 2020. TAIPEI, Taiwan , Nov.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

The Pharma Data

JUNE 7, 2022

AL01811 is a preclinical selective GBA2 inhibitor with first-in-class potential as an oral disease modifying treatment for Parkinson’s Disease Alectos to receive a $15 million upfront payment and is eligible to receive potential future development and commercial milestone payments. Biogen Inc. President and CEO at Alectos Therapeutics.

Licensing 40

Licensing Licensing Small Molecule Disease 40

The Pharma Data

NOVEMBER 29, 2020

30, 2020 07:00 UTC. Headquarters: Cambridge, UK, “Wren”) today announced that the companies have entered into an exclusive research collaboration agreement aiming to advance the discovery of novel small molecules that target ? synuclein, which is associated with the onset and progression of these diseases.

Small Molecule 52

Small Molecule Research Pharmaceutical Companies Drugs 52

The Pharma Data

FEBRUARY 4, 2021

3, 2021 /PRNewswire/ — AbbVie (NYSE: ABBV) announced financial results for the fourth quarter and full year ended December 31, 2020. AbbVie hosted an Immunology Strategic Update event on December 14, 2020 for members of the investment community. NORTH CHICAGO, Ill., Gonzalez , chairman and chief executive officer, AbbVie.

Production 52

Production Clinical Trials International Small Molecule 52

The Pharma Data

NOVEMBER 11, 2020

12, 2020 14:00 UTC. As an orally bioavailable small molecule with broad antiviral activity, SLV213 could be a valuable treatment to meet today’s urgent need to fight COVID-19 as well other life-threatening infectious diseases, such as Chagas disease, Ebola virus disease, and Nipah virus infection.”.

Treatment 52

Treatment Small Molecule Virus Pharmacokinetics 52

The Pharma Data

DECEMBER 23, 2020

LYT-100 is an anti-fibrotic and anti-inflammatory oral small molecule that has been designed to overcome the tolerability challenges associated with pirfenidone, an anti-inflammatory, anti-fibrotic drug currently on the market. The trial is ongoing in the U.S. and Europe, and PureTech Head of Innovation, Dr. Michael C.

Clinical Trials 52

Clinical Trials FDA Small Molecule Trials 52

The Pharma Data

DECEMBER 2, 2020

2, 2020 — Levels of some small molecules called metabolites in the body may affect your risk of stroke, a new analysis suggests. Levels of metabolites can change in response to factors such as disease, genetics or the environment and are indicators of overall health, the researchers noted. ” © 2020 HealthDay.

Small Molecule 52

Small Molecule Disease Research 52

Drug Target Review

MAY 23, 2023

Inflammatory bowel disease (IBD) is an umbrella term that describes complex disorders that cause chronic inflammation in the digestive tract with alternating periods of relapse and remission. A changed composition of the gut microbiota is a characteristic trait of inflammatory bowel disease. More than 6.8

Drugs 75

Drugs Small Molecule Production Disease 75

The Pharma Data

AUGUST 5, 2021

It also expands the Company’s cell therapy capabilities and manufacturing footprint in North America, building on its acquisition of Neon Therapeutics in 2020. Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. About BioNTech.

Therapies 52

Therapies Small Molecule Vaccine Science 52

The Pharma Data

JANUARY 8, 2021

When Chinook Therapeutics looks at 2021, it foresees a host of clinical trials that will bring precision medicine to the kidney disease space. Chinook’s nearest milestone is the initiation of a 300-patient Phase 3 ALIGN trial of atrasentan for IgA nephropathy (Berger’s disease) that is expected to begin early this year.

Clinical Trials 52

Clinical Trials Small Molecule Trials Disease 52

Drug Target Review

JUNE 12, 2023

Chemistry42 is a customisable and fully automated software platform launched in 2020 that integrates generative AI algorithms with computational and medicinal chemistry methods to generate novel molecules with drug-like properties, sometimes in a matter of days. How was ISM6331 generated and optimised using Chemistry42?

Metabolic Stability 92

Metabolic Stability Clinical Trials Small Molecule Pharmacokinetics 92

The Pharma Data

DECEMBER 15, 2020

16, 2020 14:00 UTC. Validated technology platform translates novel molecules from plants into first-in-class medicines. Leveraging this database of hundreds of thousands of unique chemicals and their links to biological signatures, Enveda’s machine learning algorithms predict new chemicals with the potential to treat complex diseases.

Small Molecule 52

Small Molecule Production Laboratories Engineering 52

The Pharma Data

OCTOBER 25, 2020

26, 2020 /PRNewswire/ — PTC Therapeutics , Inc. NASDAQ: PTCT), today announced the initiation of a registration-directed Phase 2/3 clinical trial to evaluate vatiquinone (PTC743) in patients with mitochondrial epilepsy, the highly morbid condition of refractory seizures in children with inherited mitochondrial disease.

Clinical Trials 52

Clinical Trials Trials Small Molecule Regulations 52

The Pharma Data

DECEMBER 21, 2020

Program focused on identifying small molecules that target a GPCR for degradation as potential therapeutic agents for gastrointestinal disorders. The principle of TPD is to use small molecules to commit the target protein into the E3 ligase-mediated degradation pathway thereby eliminating or reducing its activity.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Structure Based Drug Design (SBDD) Drugs 40

The Pharma Data

DECEMBER 12, 2020

Dedicated rare disease unit to be headquartered in Boston. 12, 2020– AstraZeneca and Alexion Pharmaceuticals, Inc. Pascal Soriot , Chief Executive Officer, AstraZeneca , said: “ Alexion has established itself as a leader in complement biology, bringing life-changing benefits to patients with rare diseases.

Regulations 75

Regulations International Disease Small Molecule 75

NIH Director's Blog: Drug Development

MAY 21, 2020

Science, 2020 We now know that the immune system of nearly everyone who recovers from COVID-19 produces antibodies against SARS-CoV-2, the novel coronavirus that causes this easily transmitted respiratory disease [1]. Preprint Posted May 5, 2020. [2] 2020 May 18. Collins FS, Stoffels P.

Virus 52

Virus Vaccine Laboratories Small Molecule 52

The Pharma Data

NOVEMBER 1, 2020

2, 2020 08:00 UTC. Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of kidney disease, neurodegenerative disease, rare mitochondrial diseases and fibrosis. This press release features multimedia. View the full release here: [link].

Clinical Pharmacology 52

Clinical Pharmacology Small Molecule Clinical Research Science 52

The Pharma Data

OCTOBER 15, 2020

16, 2020 09:20 UTC. The first-in-class degraders developed by Cullgen efficiently degrade mutated, disease causing forms of the TRK protein and subsequently inhibit cancer cell growth. Hence, Cullgen’s TRK degraders could offer patients a new therapeutic approach to treat TRK-mediated cancer diseases with reduced drug resistance. “We

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Science Disease 40

The Pharma Data

JANUARY 17, 2021

People living with LN are in need of an advanced therapy that quickly drives the disease into remission and mediates kidney damage,” said Peter Greenleaf, president and chief executive officer of Aurinia, in July 2020 when the FDA accepted the NDA to review. “We As a result, it stabilizes the podocyte in the kidney.

FDA 52

FDA Small Molecule Immune Response Hospitals 52

The Pharma Data

JANUARY 10, 2021

Comparing to Non-Small Cell Lung Cancer(NSCLC), it is still not clear about tumor driving gene in the development of SCLC, and thus it is lacking of targeted therapeutic treatment for this life threaten disease. SH ) was founded in Shenzhen on 2001, specializing in the research and development of novel small molecule drugs.

Clinical Trials 52

Clinical Trials Treatment Trials Small Molecule 52

The Pharma Data

OCTOBER 27, 2020

The objective of the Phase 3 clinical trial is to evaluate safety and effectiveness of 18 F-APN-1607 to differentiate patients with Mild Cognitive Impairment (MCI) and different stages of Alzheimer’s disease (AD) from healthy subjects. SUZHOU, China , Oct.

Clinical Trials 40

Clinical Trials Trials Small Molecule Pharmaceutical Companies 40

The Pharma Data

SEPTEMBER 15, 2020

15, 2020 /PRNewswire/ — Amgen (NASDAQ:AMGN) and MBC BioLabs today announced that BigHat Biosciences and Trilo Therapeutics have each been awarded an Amgen Golden Ticket to MBC BioLabs. Our Degradomer® class of targeted protein degraders expands on the Trilomer® concept, allowing highly specific degradation of disease-causing proteins.

Targeted Protein Degradation 52

Targeted Protein Degradation Molecular Biology Small Molecule Science 52

The Pharma Data

JUNE 26, 2021

BioNTech SE (NASDAQ: BNTX, “BioNTech” or “the Company”), announced that the first patient has been treated in its BNT111 Phase 2 cancer vaccine trial (2020-002195-12; NCT04526899). “Our vision is to harness the power of the immune system against cancer and infectious diseases. About BioNTech.

Clinical Trials 52

Clinical Trials Trials Immune Response Vaccine 52

The Open Targets Blog

APRIL 5, 2023

I asked him to tell me more about the project and its implications for target identification and prioritisation in neurodegenerative diseases. One treatment angle for neurodegenerative diseases is to dampen the Unfolded Protein Response to rescue the neurons. How did you get the idea for this project?

Small Molecule 52

Small Molecule Disease RNA Treatment 52

The Pharma Data

NOVEMBER 10, 2020

11, 2020 (GLOBE NEWSWIRE) — Calithera Biosciences, Inc. , (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced its participation at two upcoming healthcare investor conferences in November.

Small Molecule 40

Small Molecule Clinical Trials Production Treatment 40